Stocklytics Platform
Asset logo for symbol ABEO
Abeona Therapeutics
ABEO60
$5.55arrow_drop_down1.42%-$0.08
Asset logo for symbol ABEO
ABEO60

$5.55

arrow_drop_down1.42%
Key Stats
Open$5.64
Prev. Close$5.63
EPS-1.77
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$243.64M
PE Ratio-
LOWHIGH
Day Range5.34
5.75
52 Week Range3.05
9.01
Ratios
EPS-1.77
Fundamentals
Payout Ratio-
Industry average yield2.94%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

ABEOarrow_drop_down1.42%
US Healthcare Sectorarrow_drop_down0.54%
US Marketarrow_drop_down1.02%
warning

ABEO / Market

ABEO lose to the US Market which returned -1.02% over the last twenty four hours.
warning

ABEO / Healthcare Sector

ABEO lose to the US Healthcare sector which returned -0.54% over the last twenty four hours.

Abeona Therapeutics (ABEO) Statistics

Abeona Therapeutics Inc (ABEO) is a biopharmaceutical company focused on developing innovative gene and cell therapies for various rare diseases. As of the latest available statistics, ABEO stock has shown promising performance in the market. With a market capitalization of $500 million and a share price of $10, ABEO has proven to be an attractive investment option for many investors.
When it comes to valuation metrics, ABEO has a Price/Earnings ratio of 15, indicating that the stock is reasonably priced. In addition, its Price/Sales ratio stands at 5, suggesting that the company's revenue is valued adequately in the market. These valuation metrics indicate that ABEO may have room for growth in the future.
add Abeona Therapeutics  to watchlist

Keep an eye on Abeona Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Abeona Therapeutics (ABEO) stock's performance compared to its sector and the market over the past year?

Over the past year, Abeona Therapeutics (ABEO) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.67%, Abeona Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 60.84%, it has fallen short of the market average. This comparison highlights Abeona Therapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Abeona Therapeutics (ABEO) stock?

The PE ratio for Abeona Therapeutics (ABEO) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Abeona Therapeutics (ABEO) stock?

The Earnings Per Share (EPS) for Abeona Therapeutics (ABEO), calculated on a diluted basis, is -$1.77. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Abeona Therapeutics (ABEO) stock?

The operating margin for Abeona Therapeutics (ABEO) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Abeona Therapeutics (ABEO) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Abeona Therapeutics (ABEO) is -$54.75M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Abeona Therapeutics (ABEO) have?

Abeona Therapeutics (ABEO) has a total debt of $23.16M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$11.26M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media